RALEIGH, N.C., Dec. 14, 2016 /PRNewswire/ -- BioDelivery
Sciences International, Inc. (NASDAQ: BDSI) announced that
Peter Ginsberg has joined the
company as Vice President of Business Development. Mr.
Ginsberg joins BDSI with over 25 years of business development and
other closely related experience.
Most recently, Mr. Ginsberg headed business development for
United Therapeutics, where he led the sale of the company's
Priority Review Voucher for $350
million. Prior to United Therapeutics, Mr. Ginsberg
was Vice President of Business and Technology Development for the
North Carolina Biotechnology Center, where his group financed and
advised emerging biotechnology companies. Previously, Mr.
Ginsberg was responsible for acquisitions and licensing
transactions as Vice President of Business Development and
Strategic Planning for SurModics and he also spent 15 years in the
healthcare investment industry, during which time he was named a
Wall Street Journal All-Star as Piper
Jaffray's lead biotechnology analyst. He earned an
A.B. from Princeton University and an
M.B.A. from the Tuck School of Business at Dartmouth College.
"We are very pleased to have Peter join BDSI given the depth and
level of experience he brings as we look to enhance our focus on
business development opportunities, particularly given the recent
reacquisition of BELBUCA®," said Dr. Mark A. Sirgo, President and Chief Executive
Officer. "This hire will allow us to augment our efforts
behind business opportunities for BELBUCA and BUNAVAIL®
both outside as well as inside the U.S."
About BioDelivery Sciences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
specialty pharmaceutical company with a focus in the areas of pain
management and addiction medicine. BDSI is utilizing its
novel and proprietary BioErodible MucoAdhesive (BEMA®)
technology and other drug delivery technologies to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSI's development strategy focuses on the utilization of the
FDA's 505(b)(2) approval process. This regulatory pathway creates
the potential for more timely and efficient approval of new
formulations of previously approved therapeutics.
BDSI's area of focus is the development and commercialization of
products in the areas of pain management and addiction. These are
areas where BDSI believes its drug delivery technologies and
products can best be applied to address critical unmet medical
needs. BDSI's marketed products and those in development
address serious and debilitating conditions such as breakthrough
cancer pain, chronic pain, painful diabetic neuropathy and opioid
dependence. BDSI's headquarters is in Raleigh, North
Carolina.
For more information,
please visit or follow us:
|
|
Internet:
|
www.bdsi.com
|
Facebook:
|
Facebook.com/BioDeliverySI
|
Twitter:
|
@BioDeliverySI
|
Cautionary Note on Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of BioDelivery Sciences International,
Inc. (the "Company") related thereto contain, or may contain, among
other things, certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve significant
risks and uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the results of the new Company employee and related business
development projects described herein) may differ significantly
from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS® and
BUNAVAIL® are registered trademarks of BioDelivery
Sciences International, Inc. The BioDelivery Sciences and
BUNAVAIL logos are trademarks owned by BioDelivery Sciences
International, Inc. BELBUCA® is a trademark currently owned
by Endo Pharmaceuticals. All other trademarks and tradenames
are owned by their respective owners.
© 2016 BioDelivery Sciences International, Inc. All rights
reserved.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biodelivery-sciences-announces-the-hiring-of-peter-ginsberg-as-vice-president-of-business-development-300377790.html
SOURCE BioDelivery Sciences International, Inc.